Tag: Octarine Bio - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients

Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients

Post published:September 8, 2021
Post category:Press Release

Read more about the article Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Post published:September 8, 2021
Post category:Press Release

Read more about the article Octarine Bio announces the expansion of its Scientific Advisory Board

Octarine Bio announces the expansion of its Scientific Advisory Board

Post published:July 19, 2021
Post category:Press Release

Read more about the article Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Post published:March 11, 2021
Post category:Press Release

Read more about the article Nick Milne, Co-founder and CSO at Octarine Bio

Nick Milne, Co-founder and CSO at Octarine Bio

Post published:November 19, 2020
Post category:Interview

Read more about the article European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives

European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives

Post published:November 12, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.